Personalized Progeroid Disease Treatment and Cardiovascular Risk Management System

A next-generation system for personalized treatment of progeroid diseases, leveraging genomics, proteomics, and customized combination therapies to predict and mitigate cardiovascular disease risk

The original patent addressed the treatment of progeroid diseases and conditions, but its combination therapies were limited to fixed dosages and lacked personalized approaches. The new inventive concept addresses these limitations by integrating genomics, proteomics, and simulation modeling to provide customized treatment plans and cardiovascular risk assessments

The system consists of three modules: a genomics module for identifying genetic mutations associated with progeroid diseases, a proteomics module for detecting aberrant lamin A protein levels, and a therapeutic module for administering customized combination therapies based on the identified mutations and detected protein levels. The system also includes a simulation engine for predicting the efficacy of various combination therapies on cellular aging and a database of known progeroid disease-causing mutations and therapeutic compounds. The kit for treating atherosclerosis includes a farnesyltransferase inhibitor, an mTOR inhibitor, and a guide for administering a customized combination therapy based on the subject's genetic profile and disease severity

The new inventive concept introduces a paradigm shift in personalized medicine by integrating genomics, proteomics, and simulation modeling to provide customized treatment plans and cardiovascular risk assessments. The inventive step lies in the combination of these modules and the simulation engine, which enables the prediction of treatment efficacy and the identification of novel therapeutic targets

Alternative embodiments may include the use of machine learning algorithms to analyze genomic and proteomic data, the integration of wearable devices for real-time monitoring of cardiovascular risk, or the development of companion diagnostics for identifying subjects most likely to benefit from customized combination therapies

The inventive concept has significant commercial potential in the pharmaceutical and biotechnology industries, particularly in the areas of personalized medicine, cardiovascular disease prevention, and progeroid disease treatment. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to develop and implement personalized treatment approaches for progeroid diseases